Zobrazeno 1 - 10
of 64
pro vyhledávání: ''
Autor:
Daniel Okin, David C. Christiani, Amita Sharma, Sydney B. Montesi, Kristin M. D’Silva, Ioana A. Dobre, Angela J. Frank
Publikováno v:
Clin Lung Cancer
Background Immune checkpoint inhibitors (ICIs), such as programmed cell death 1 (PD-1) inhibitors, are used to treat multiple cancers. Limited data exist as to the use of ICIs in patients with coexistent interstitial lung disease (ILD). We conducted
Autor:
Christopher J. Rivard, Anders Berglund, Simon Ekman, Hui Yu, Linnea La Fleur, Johan Botling, Patrick Micke, Steinar Solberg, Odd Terje Brustugun, Fred R. Hirsch
Publikováno v:
Clinical Lung Cancer. 22:e555-e562
Background Recently, anti–programmed cell death 1 (PD-1) and anti–programmed cell death ligand 1 (PD-L1) immunotherapies have yielded promising outcomes for patients with advanced non–small cell lung cancer (NSCLC) and led to great interest in
Autor:
Yizhuo Zhao, Jialin Qian, Tianqing Chu, Baohui Han, Runbo Zhong, Yuqing Lou, Jianlin Xu, Qing Chang, Minfang Lv, Yanwei Zhang, Huiping Qiang, Jiajun Teng
Publikováno v:
Clinical Lung Cancer. 22:e395-e404
Introduction Continuing tyrosine kinase inhibitor (TKI) therapy may be beneficial when patients with non–small-cell lung cancer and EGFR mutations experience gradual disease progression after initial EGFR-TKI treatment. We aimed to compare the effi
Publikováno v:
Clinical Lung Cancer. 22:e193-e200
Background Many studies have shown that invasive pulmonary aspergillosis, cryptococcosis, and mucormycosis can mimic radiographic and clinical features of primary lung cancer. However, more research surveying the incidence and outcomes of these funga
Autor:
Heung Tae Kim, Ji-Youn Han, Youngjoo Lee, Jin Soo Lee, Byung-Ho Nam, Hyae Young Kim, Hye Jin An, Geon Kook Lee
Publikováno v:
Clinical Lung Cancer. 21:e572-e582
Background We aimed to evaluate whether intercalated combination of EGFR tyrosine kinase inhibitor gefitinib and chemotherapy improves survival outcomes in never-smokers with advanced lung adenocarcinoma. Patients and Methods Never-smokers with chemo
Publikováno v:
Clinical Lung Cancer. 22:e157-e159
Clinical Practice Points • Osimertinib is widely used in patients with lung cancer with EGFR T790M after EGFR TKI treatment with high efficacy and approved in first-line treatment for all EGFR positive patients. However, the resistance profile to o
Autor:
Eugenia Lamont, Joerg Lindenmann, Alfred Maier, Josef Smolle, Freyja Maria Smolle-Juettner, Udo Anegg, Melanie Fediuk, Christian Porubsky, Nicole Fink-Neuboeck
Publikováno v:
Clinical Lung Cancer. 21:333-340
Introduction Better treatment options entail the risk of multiple tumors in a patient’s lifetime. We studied the incidence, risk factors, and prognostic impact of second primaries and other malignancies in patients with operated non–small-cell lu
Autor:
Mario Miccoli, Iacopo Petrini, Marzia Del Re, Antonio Chella, Marina Chiara Garassino, Giulia Gianfilippo, Daniele Pozzessere, Francesca Mazzoni, Stefania Crucitta, Giuliana Restante, Eleonora Rofi, Romano Danesi, Simona Valleggi
Publikováno v:
Clinical Lung Cancer. 21:232-237
Background Insights into the mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) could provide important information for further patient management, including the choice of second-line treatment. The E
Publikováno v:
Clinical Lung Cancer. 21:195-203
Retrospective studies have shown an increased risk of second primary lung cancer in patients with a history of head and neck cancer (HNC). No population-based study has examined the overall survival (OS) outcomes of patients with second primary non-s
Publikováno v:
Clinical Lung Cancer. 20:e620-e630
Two main categories of epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) patients are deletions in exon 19 and L858R in exon 21. Treatments of advanced NSCLC patients with these mutations are well documented, and